High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma Previously Treated with CHOP-based Chemotherapy: A Study from the Consortium for Improving Survival of Lymphoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hyun, Shin Young | - |
dc.contributor.author | Cheong, June-Won | - |
dc.contributor.author | Kim, Soo-Jeong | - |
dc.contributor.author | Min, Yoo Hong | - |
dc.contributor.author | Yang, Deok-Hwan | - |
dc.contributor.author | Ahn, Jae-Sook | - |
dc.contributor.author | Lee, Won-Sik | - |
dc.contributor.author | Ryoo, Hun-Mo | - |
dc.contributor.author | Do, Young Rok | - |
dc.contributor.author | Lee, Ho Sup | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Oh, Sung Yong | - |
dc.contributor.author | Suh, Cheolwon | - |
dc.contributor.author | Yhim, Ho-Young | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.date.available | 2020-02-28T18:43:28Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2014-01 | - |
dc.identifier.issn | 1083-8791 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12920 | - |
dc.description.abstract | We conducted a multicenter retrospective study to compare the efficacy and toxicity of various chemomobilization regimens: high-dose (HD) cyclophosphamide, HD etoposide (VP-16), and platinum-based chemotherapies. We reviewed the experiences of 10 institutions with 103 non-Hodgkin lymphoma patients who had previously only been treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)based chemotherapy. The mobilization yields for each regimen were analyzed. HD VP-16 mobilized a significantly higher median number of CD34(+) cells (16.22 x 10(6) cells/kg) than HD cyclophosphamide (4.44 x 10(6) cells/kg) or platinum-based chemotherapies (6.08 x 10(6) cells/kg, P < .001). The rate of successful mobilization (CD34(+) cell count >= 5.0 x 10(6) cells/kg) was also significantly higher for HD VP-16 (86%) than for HD cyclophosphamide (45%) or platinum-based chemotherapies (61%, P = .004). The successful mobilization rate on day 1 of 72% for HD VP-16 was significantly higher than the rates for HD cyclophosphamide (13%) and platinum-based chemotherapies (26%, P < .001). In multivariate analysis, HD VP-16 was a significant predictor of successful mobilization (P = .014; odds ratio, 5.25; 95% confidence interval, 1.40 to 19.63). Neutropenic fever occurred in 67% of patients treated with HD VP-16. The incidence was similar for HD cyclophosphamide (58%, P = .454) but was significantly lower for platinum-based chemotherapies (12%, P < .001). However, fatal (grade >= 4) infection and treatment-related mortality were not observed in this study. In conclusion, the mobilization yield was significantly influenced by the chemomobilization regimen, and HD VP-16 was a highly effective mobilization regimen in patients with non-Hodgkin lymphoma. (C) 2014 American Society for Blood and Marrow Transplantation. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.relation.isPartOf | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | - |
dc.subject | BLOOD PROGENITOR CELLS | - |
dc.subject | G-CSF | - |
dc.subject | MOBILIZATION REGIMEN | - |
dc.subject | POOR MOBILIZATION | - |
dc.subject | RISK-FACTORS | - |
dc.subject | CYCLOPHOSPHAMIDE | - |
dc.subject | IMPACT | - |
dc.subject | MYELODYSPLASIA | - |
dc.subject | STRATEGIES | - |
dc.subject | CANCER | - |
dc.title | High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma Previously Treated with CHOP-based Chemotherapy: A Study from the Consortium for Improving Survival of Lymphoma | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000329683400012 | - |
dc.identifier.doi | 10.1016/j.bbmt.2013.10.012 | - |
dc.identifier.bibliographicCitation | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, v.20, no.1, pp.73 - 79 | - |
dc.identifier.scopusid | 2-s2.0-84890961475 | - |
dc.citation.endPage | 79 | - |
dc.citation.startPage | 73 | - |
dc.citation.title | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | - |
dc.citation.volume | 20 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Cyclophosphamide | - |
dc.subject.keywordAuthor | Etoposide | - |
dc.subject.keywordAuthor | Platinum | - |
dc.subject.keywordAuthor | Stem cell mobilization | - |
dc.subject.keywordAuthor | Non-Hodgkin lymphoma | - |
dc.subject.keywordPlus | BLOOD PROGENITOR CELLS | - |
dc.subject.keywordPlus | G-CSF | - |
dc.subject.keywordPlus | MOBILIZATION REGIMEN | - |
dc.subject.keywordPlus | POOR MOBILIZATION | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | CYCLOPHOSPHAMIDE | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | MYELODYSPLASIA | - |
dc.subject.keywordPlus | STRATEGIES | - |
dc.subject.keywordPlus | CANCER | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Transplantation | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Transplantation | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.